Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

growth hormone disorder

- PMLiVE

Merck forges cancer-focused big data alliance with Palantir

Plans to develop a collaborative analytics platform to accelerate research and improve outcomes

- PMLiVE

Merck pays Vertex $230m upfront for cancer programmes

Licences four DNA damage and repair programmes with first-in-class or best-in-class potential

- PMLiVE

Merck & Co’s Keytruda muscles further ahead of rivals in lung cancer

Granted accelerated review by FDA for use in combination with chemotherapy

- PMLiVE

The future of biotech

What impact will the sector, and its R&D performance, have on pharma?

Roche Basel Switzerland

FDA delays verdict on Roche’s MS drug Ocrevus

Additional manufacturing data postpones US verdict until 28 March 2017

- PMLiVE

QuintilesIMS launches European oncology data-gathering initiative

Will collaborate with Bristol-Myers Squibb, Lilly, Merck KGaA and Pfizer

Bayer symbol

Bayer helps bankroll new stem cell company BlueRock

Start-up receives $225m to develop cardiovascular and neurodegenerative disease therapies

- PMLiVE

FDA starts speedy review of Merck/Pfizer’s PD-L1 inhibitor

If approved avelumab would be first approved cancer immunotherapy for metastatic MCC

dengue fever mosquito

Dosing of GSK’s malaria vaccine due to start in 2018

WHO sanctions pilot programme in sub-Saharan Africa to begin gathering field data

- PMLiVE

GSK tops Access to Medicines Index for fifth time running

Leads J&J and Novartis in 'needs-orientation' while Roche and Astellas lag

- PMLiVE

Merck’s pharma unit faces tougher 2017 as fertility boost recedes

Looks to new products to drive growth as fertility drug rivals return to market

- PMLiVE

NICE set to reject Merck’s Erbitux for head and neck cancer

Draft guidance rules the treatment does not provide value for money

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links